Assessing Indivior (INDV) Valuation Following a 96% Share Price Surge This Year

Simply Wall St.

Oct 15

Indivior (INDV) shares have moved up around 3% over the past week, catching the attention of investors interested in the company’s recent performance. The stock is trading at $24.54 following a strong...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2575173025"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575173025\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575173025?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2025-10-15 23:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575173025","market":"hk","top_or_hot":-1,"title":"Assessing Indivior (INDV) Valuation Following a 96% Share Price Surge This Year","media":"Simply Wall St.","content":"<div>\n<p>Indivior (INDV) shares have moved up around 3% over the past week, catching the attention of investors interested in the company’s recent performance. The stock is trading at $24.54 following a strong...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indv/indivior/news/assessing-indivior-indv-valuation-following-a-96-share-price\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Indivior (INDV) Valuation Following a 96% Share Price Surge This Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Indivior (INDV) Valuation Following a 96% Share Price Surge This Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-15 23:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indv/indivior/news/assessing-indivior-indv-valuation-following-a-96-share-price><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Indivior (INDV) shares have moved up around 3% over the past week, catching the attention of investors interested in the company’s recent performance. The stock is trading at $24.54 following a strong...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indv/indivior/news/assessing-indivior-indv-valuation-following-a-96-share-price\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INDV","symbol_name":"INDIVIOR PLC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indv/indivior/news/assessing-indivior-indv-valuation-following-a-96-share-price","article_id":"2575173025","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indv/indivior/news/assessing-indivior-indv-valuation-following-a-96-share-price","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2575173025","pubTimestamp":1760541977,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Indivior (INDV) shares have moved up around 3% over the past week, catching the attention of investors interested in the company’s recent performance. The stock is trading at $24.54 following a strong year-to-date run.\nSee our latest analysis for Indivior.\nIndivior’s momentum has been tough to ignore lately, with a 96% share price return so far this year and a 207% total return for shareholders over the past twelve months. After such a strong run in recent months, some investors are watching...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"INDV":"INDIVIOR PLC","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4007":"制药"},"translate_title":"今年股价飙升96%后评估Indivior(INDV)估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"INDV":1.5},"content_text":"Indivior (INDV) shares have moved up around 3% over the past week, catching the attention of investors interested in the company’s recent performance. The stock is trading at $24.54 following a strong year-to-date run.\nSee our latest analysis for Indivior. Indivior’s momentum has been tough to ignore lately, with a 96% share price return so far this year and a 207% total return for shareholders over the past twelve months. After such a strong run in recent months, some investors are watching to see if confidence continues to build or if the stock starts to settle back down. If Indivior’s surge has you rethinking your watchlist, now is the perfect time to broaden your search and discover fast growing stocks with high insider ownership With Indivior’s share price surging to fresh highs, the big question now is whether the stock still offers value at these levels or if the recent gains simply reflect the market’s expectations for future growth. Is there room left for buyers, or has the opportunity already been priced in? AdvertisementPrice-to-Earnings of 57.8x: Is It Justified? Indivior currently trades at a price-to-earnings (P/E) ratio of 57.8x, putting it far ahead of both its peer group and the broader US Pharmaceuticals industry. With a last close of $24.54, the market is pricing in powerful earnings growth and strong future prospects, but also heightened expectations. The price-to-earnings ratio is widely followed as a quick measure of how much investors are paying for a company’s recent profits. In Indivior’s case, a high P/E could reflect optimism around forecasted profit growth, especially following its transition to profitability. However, at 57.8x, Indivior’s P/E is substantially higher than the US Pharmaceuticals industry average of 17.9x and the peer group average of 20.9x. It also stands out against the estimated fair P/E ratio of 29.7x. This shows that the market is pricing in expectations well above historical or sector norms. This gap could narrow if Indivior delivers on aggressive profit growth, or widen if it falls short. Explore the SWS fair ratio for Indivior Result: Price-to-Earnings of 57.8x (OVERVALUED) However, risks such as slower than expected revenue growth or failing to meet high market expectations could put pressure on Indivior’s lofty valuation. Find out about the key risks to this Indivior narrative. Another View: Deep Discount to Intrinsic Value? While the high price-to-earnings ratio suggests Indivior could be expensive, our DCF model tells a different story. Based on projected future cash flows, Indivior’s current price appears to be trading at a steep 65% discount to its estimated fair value. Could this point to a hidden opportunity, or does it reflect hidden risks? Look into how the SWS DCF model arrives at its fair value. INDV Discounted Cash Flow as at Oct 2025Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Indivior for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.  Build Your Own Indivior Narrative If you want to dig deeper or reach your own conclusions, you can easily build a personal view using the data in just a few minutes with Do it your way. A great starting point for your Indivior research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision. Looking for more investment ideas? Stay ahead of the market and never limit yourself to just one opportunity. Smart investors always keep their options open with fresh, high-potential stocks.  Tap into tomorrow’s innovation by checking out these 25 AI penny stocks, which are pushing the boundaries of artificial intelligence and automation. Grow your income stream and strengthen your portfolio with these 18 dividend stocks with yields > 3%, offering solid yields and proven resilience. Get in early on future tech breakthroughs with these 26 quantum computing stocks, accelerating advancements in quantum computing and scientific progress.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}